In the case of AFP, a reduction of more than 50% of the basal concentration after four weeks following localized concurrent chemoradiotherapy is a positive predictor for the effectiveness of the therapy in patients with progressed HCC [37]. This evidence concerns the gene AFP and hepatocellular carcinoma.